Table 1.

Comparison of the frequency of mutations in the coagulation and complement pathway between primary tumours from TCGA-database and brain metastases of our cohort.

TOTAL	Brain Metastasis	TCGA_Primary	OR	Permutation Test P-value		Total
Mutated	17	578	5,796691	3,70E-06	Number of samples	2945
Not_Mutated	12	2367			Mutated Samples	578
Frequency	0,586206897	0,196264856			Frequency	0,196265
BREAST	Brain Metastasis	TCGA_Primary	OR	Permutation Test P-value		brca	Total
Mutated	7	155	9,932555	1,82E-04	Number of samples	1258	1258
Not_Mutated	5	1103			Mutated Samples	155	155
Frequency	0,583333333	0,123211447			Frequency	0,123211	0,1232114
LUNG	Brain Metastasis	TCGA_Primary	OR	Permutation Test P-value		luad	lusc	sclc	Total
Mutated	7	313	3,498197	5,34E-02	Number of samples	447	178	158	783
Not_Mutated	3	470			Mutated Samples	165	79	69	313
Frequency	0,7	0,399744572			Frequency	0,369127	0,443820	0,436709	0,399745
KIDNEY	Brain Metastasis	TCGA_Primary	OR	Permutation Test P-value		kich	kirc	kirp	Total
Mutated	3	110	5,396801	4,25E-02	Number of samples	66	556	282	904
Not_Mutated	4	794			Mutated Samples	9	81	20	110
Frequency	0,428571429	0,121681416			Frequency	0,136364	0,145683	0,070922	0,121681

We compare frequencies of mutations based on the origin of primary tumours (breast, lung and kidney). Mutational profile of these tumours, analysed according to the pathways, indicates that coagulation and complement cascade genes carry mutations at frequency significantly lower than brain metastases in each of the 3 different datasets (breast, lung and kidney cancer).

OR: odds ratio

brca: breast carcinoma; luad: lung adenocarcinoma; lusc: lung squamous cell carcinoma; sclc: small cell lung cancer; kich: kidney chromophobe; kirc: kidney renal clear cell carcinoma; kirp: kidney renal papillary cell.